Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study

被引：0

作者：

le Coutre, Philipp D. ^{[1
]}

Giles, Francis J. ^{[2
,3
]}

Pinilla-Ibarz, Javier ^{[4
]}

Larson, Richard A. ^{[5
]}

Gattermann, Norbert ^{[6
]}

Ottmann, Oliver G. ^{[7
]}

Hochhaus, Andreas ^{[8
]}

Radich, Jerald P. ^{[9
]}

Saglio, Giuseppe ^{[10
]}

Hughes, Timothy P. ^{[11
]}

Martinelli, Giovanni ^{[12
]}

Kim, Dong-Wook ^{[13
]}

Branford, Susan ^{[11
]}

Mueller, Martin C. ^{[14
]}

Shou, Yaping ^{[15
]}

Novick, Steven ^{[16
]}

Fan, Xiaolin ^{[16
]}

Cortes, Jorge E. ^{[17
]}

Baccarani, Michele ^{[12
]}

Kantarjian, Hagop M. ^{[17
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Natl Univ Ireland Galway, Galway, Ireland

[3] Trinity Coll Dublin, Galway, Ireland

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[7] Univ Klin Frankfurt, Med Klin 2, MRD Lab, Frankfurt, Germany

[8] Univ Klinikum Jena, Jena, Germany

[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[10] Univ Turin, Orbassano, Italy

[11] Royal Adelaide Hosp, SA Pathol, Adelaide, SA 5000, Australia

[12] Univ Bologna, Bologna, Italy

[13] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[14] Univ Heidelberg, Med Klin 3, Med Fak Mannheim, D-6800 Mannheim, Germany

[15] Novartis Inst BioMed Res, Cambridge, MA USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1610 / 1610

页数：1

共 50 条

[1] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
Giles, F. J.
le Coutre, P. D.
Pinilla-Ibarz, J.
Larson, R. A.
Gattermann, N.
Ottmann, O. G.
Hochhaus, A.
Radich, J. P.
Saglio, G.
Hughes, T. P.
Martinelli, G.
Kim, D-W
Novick, S.
Gillis, K.
Fan, X.
Cortes, J.
Baccarani, M.
Kantarjian, H. M.
LEUKEMIA, 2013, 27 (01) : 107 - 112
[2] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F J Giles
P D le Coutre
J Pinilla-Ibarz
R A Larson
N Gattermann
O G Ottmann
A Hochhaus
J P Radich
G Saglio
T P Hughes
G Martinelli
D-W Kim
S Novick
K Gillis
X Fan
J Cortes
M Baccarani
H M Kantarjian
Leukemia, 2013, 27 : 107 - 112
[3] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
Kantarjian, H. M.
Giles, F. J.
Hochhaus, A.
Bhalla, K. N.
Ossenkoppele, G. J.
Gattermann, N.
Haque, A.
Gallagher, N.
Castagnetti, F.
le Coutre, P.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
Clark, R.
Kantarjian, H. M.
Giles, F. J.
Hochhaus, A.
Bhalla, K. N.
Ossenkoppele, G.
Gattermann, N.
Haque, A.
Gallagher, N.
Baccarani, M.
le Coutre, P.
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
[5] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
Kantarjian, H.
Giles, F. G.
Bhalla, K. N. P.
Pinilla, J.
Larson, R. A.
Gattermann, N.
Ottmann, O. G.
Wang, J.
Gallagher, N. J.
Baccarani, M.
Le Coutre, P. D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 254 - 255
[6] BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Kim, D.
Saglio, G.
Martinelli, G.
Shou, Y.
Stein, A. M.
Woodman, R. C.
Kantarjian, H.
Hughes, T. P.
Radich, J. P.
Hochhaus, A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[7] Five-year follow-up of patients with imatinib-resistant or - intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib
Shah, N. P.
Cortes, J. E.
Schiffer, C. A.
Guilhot, F.
Brummendorf, T. H.
Chen, A. C.
Healey, D.
Lambert, A.
Saglio, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
Hochhaus, A.
Saglio, A.
Kantarjian, H.
Haque, A.
Shou, Y.
Woodman, R. C.
Hughes, T. P.
Radich, J. P.
Martinelli, G.
Kim, D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[9] Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study
Clark, R.
le Coutre, P.
Giles, F. J.
Hocchaus, A.
Haque, A.
Gallagher, N.
Baccarani, M.
Kantarjian, H. M.
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 40
[10] Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.
Shah, Neil P.
Kantarjian, Hagop
Kim, Dong-Wook
Hochhaus, Andreas
Saglio, Giuseppe
Guilhot, Francois
Schiffer, Charles Alan
Steegmann, Juan Luis
Mohamed, Hesham
Dejardin, David
Healey, Diane I.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →